We evaluated the treatment results of nonfunctioning @entity977 in the era of radiosurgery. Between January 1994 and December 2003, we operated on 44 @entity1 with nonfunctioning @entity977 . 43 @entity1 were operated on by transsphenoidal surgery and one @entity1 was operated on by the transcranial approach. Total removal was able to be achieved in 13 @entity1 (30%). Gamma knife radiosurgery was performed for @entity41 in 26 @entity1 and for recurrence in 2 @entity1 . The mean @entity5 diameter at the gamma knife radiosurgery was 18.2 mm (7.9 to 26.3 mm). The treatment dose was a mean of 12.3 Gy (8 to 16 Gy) to the @entity5 margin. The mean follow-up period after radiosurgery was 36.4 months. @entity5 growth control was able to be achieved in 26 @entity1 (93%). Two @entity1 (7%) required adrenal and thyroid hormonal replacement during the follow-up period after radiosurgery due to radiation-induced @entity2744 . None of the @entity1 suffered from new @entity129 . This included @entity1781 . Surgical resection using transsphenoidal surgery and subsequent gamma knife radiosurgery for residual and recurrent @entity5 proved to have a highly effective @entity5 growth control rate, and maintained the quality of life in @entity1 with nonfunctioning @entity977 .

[The usefulness of adjuvant therapy using gamma knife radiosurgery for the recurrent or residual nonfunctioning XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity129 :: ('MESH:D003389', 'Disease') :: ['cranial nerve deficits'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor'] @entity2744 :: ('MESH:C567425', 'Disease') :: ['endocrinopathy'] @entity1781 :: ('MESH:D009901', 'Disease') :: ['optic neuropathy'] @entity977 :: ('MESH:D010911', 'Disease') :: ['pituitary adenomas']
@entity977 :: (MESH:D010911,Disease) :: ['pituitary adenomas']
